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Abstract
Oncolytic viruses aim to specifically kill tumor cells. A major challenge is the effective targeting of disseminated tumors in
vivo. We retargeted herpes simplex virus (HSV) tropism to HER-2 oncoprotein p185, overexpressed in ovary and breast
cancers. The HER-2-retargeted R-LM249 exclusively infects and kills tumor cells expressing high levels of human HER-2. Here,
we assessed the efficacy of systemically i.p. delivered R-LM249 against disseminated tumors in mouse models that
recapitulate tumor spread to the peritoneum in women. The human ovarian carcinoma SK-OV-3 cells implanted
intraperitoneally (i.p.) in immunodeficient Rag22/2;Il2rg2/2 mice gave rise to a progressive peritoneal carcinomatosis which
mimics the fatal condition in advanced human patients. I.p. administration of R-LM249 strongly inhibited carcinomatosis,
resulting in 60% of mice free from peritoneal diffusion, and 95% reduction in the total weight of neoplastic nodules.
Intraperitoneal metastases are a common outcome in breast cancer: i.p. administration of R-LM249 strongly inhibited the
growth of ovarian metastases of HER-2+ MDA-MB-453 breast cells. Brain metastases were also reduced. Cumulatively, upon
i.p. administration the HER-2-redirected oncolytic HSV effectively reduced the growth of ovarian and breast carcinoma
disseminated to the peritoneal cavity.
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Introduction
The past decades have witnessed remarkable progresses in the
ability to treat numerous cancers by means of surgery, chemio-
and radiotherapy, or combinations thereof. Nonetheless, there
remains a tremendous burden of tumors not sensitive or accessible
to standard treatments. Oncolytic virotherapy exploits the intrinsic
ability of viruses to kill the target cell and simultaneously to spread
to other target cells. A key requirement is that the virus specifically
targets cancer cells [1]. Herpes simplex virus- 1 (HSV-1) is being
actively investigated in preclinical and phase 1–3 clinical studies as
it lends itself to numerous genetic modifications that make it
cancer-specific [2,3].
The strategy pursued in our laboratories is to modify HSV-1
tropism, and efficiently retarget the virus to cancer-associated cell-
surface molecules, such as the human epithelial growth factor
receptor 2 (HER-2), a member of the tyrosine kinase receptors [4–
9]. The clinical impact of the HER-2 oncogene stems from the fact
that it is overexpressed in human breast and ovary carcinomas
(.200,000 new cancer cases each year in the U.S.), and correlates
with worsened prognosis. Because of these properties, HER-2 is
currently the target of antibody-based (trastuzumab) therapies, or
small molecule tyrosine kinase inhibitors.
We took advantage of the fact that HSV encodes a multipartite
fusion/entry apparatus made of four essential glycoproteins, and
that one of these, gD, is the major determinant of the viral tropism
[10]. Replacement of the Ig-folded gD core with a single chain
antibody to HER-2 subverts the viral tropism, and enables HSV to
selectively infect HER-2+ cancer cells and spare the usual targets.
By this strategy, the killing capacity of wt-virus is fully preserved,
and the high safety profile has not been achieved at the expenses of
replication, as was the case in earlier oncolytic-HSV (o-HSV)
which were deleted of virulence genes, and overall attenuated in
replication capacity [11,12]. Previous studies from our laboratories
showed that the HER-2-retargeted R-LM249 exerts antitumor
activity when administered intratumorally to nude mice bearing
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HER-2-hyperexpressing human tumors [6]. A single injection
dramatically impaired tumor growth. Repeated injections of R-
LM249 doses higher than 106 pfu left 60% of mice tumor-free,
and dramatically reduced the tumor size in the remaining 40%.
Recently, a HSV retargeted to HER-2 showed efficient antitumor
activity in an intracranial model of high-grade glioma in
immunosuppressed and immunocompetent mice [7,9]. Overall,
these findings demonstrated that R-LM249 is effective in killing
HER-2+ tumors in vivo, when administered locally [6].
The major clinical problem of HER-2+ neoplasms is dissem-
inated disease, not the primary tumors which are usually removed
surgically, coupled to the development of cells resistant to the
biological inhibitors. Ovarian cancer disseminates within the
peritoneal cavity, thus hampering surgical resection, and frequent-
ly produces voluminous peritoneal ascites [13]. Breast cancer
disseminates systemically, most frequently to lungs, peritoneal
organs, bones, brain in addition to peritoneal cavity [14]. Here we
performed the preclinical evaluation of i.p. administered R-
LM249 against peritoneal metastases of human ovarian and breast
cancers in murine hosts. We show that the i.p.-administered HER-
2-redirected HSV effectively inhibits peritoneal dissemination of
HER-2+ ovarian and mammary carcinomas.
Results
In vitro activity of R-LM249 and trastuzumab against
ovary and mammary cancer cells
In vitro R-LM249 killed all the HER-2+ human cancer cells lines,
both of ovary (SK-OV-3) and mammary (MDA-MB-453 and BT-
474) origin, but not the HER-2-low/negative MDA-MB-231 cells
(Fig. 1A). Microscopical examination of R-LM249-treated BT-474
and SK-OV-3 cultures revealed some residual cells, possibly
accounting for 10% viability reported in the graph at 6 days.
When such cells were cultured they were unable to proliferate, and
therefore most likely already committed to death. Of note, SK-
OV-3 and MDA-MB-453 cells are resistant to the growth
inhibition by trastuzumab (Fig. 1B) [15]. Thus, HER-2-redirected
HSV is effective against HER-2+ trastuzumab-resistant cells, an
important property in view of clinical application of R-LM249.
Therapy of peritoneal carcinomatosis of HER-2+ ovarian
carcinoma
Previously, we showed that R-LM249 exerts anti-tumor activity
against subcutaneously-injected human ovary cancer cells. Here, we
investigated the therapeutic activity of R-LM249 against the
intraperitoneal (i.p.) growth of SK-OV-3 cells. In a first set of
experiments, SK-OV-3 cells were injected i.p. in athymic nude mice.
Fig. 2 shows that repeated i.p. administrations of R-LM249
significantly delayed the growth of SK-OV-3 peritoneal carcinoma-
tosis, resulting in a prolongation of median survival time from 103 to
440 days. The majority of treated mice died when they reached the
lifetime expected for nude mice, not because of xenograft growth. It
can be seen that the growth of SK-OV-3 tumors in nude mice was
very slow, in agreement with previous reports [16], and the whole
experiment depicted in Figure 2 took one and a half year, clearly
hindering further investigations in this model system.
Recently, one of our laboratories showed that Rag22/2;Il2rg2/2
mice, which lack T, B and NK responses, are superior to nude mice
for studies on human tumors [17,18]. Here, we asked whether the
novel model could be employed to evaluate the oncolytic therapy of
HER-2+ ovarian carcinoma. SK-OV-3 cells grew i.p. in all Rag22/2;
Il2rg2/2mice in a few weeks, and gave also rise to ascitic fluid in most
cases; this enabled us to reliably use a fixed end-point of 6 weeks and
allowed a quantitative evaluation of peritoneal carcinomatosis (Fig. 3
and Fig. S1). Therapy with R-LM249 produced a strong inhibition of
tumor growth, resulting in the absence of ascites in all treated mice and
reducing the overall tumor burden by 95% (Figs. 3A–E). EGFP
fluorescence, indicative of R-LM249 persistence and expression, hence
of virus-susceptible cells, was observed at sacrifice in some residual
peritoneal masses of treated mice.
Figure 1. In vitro sensitivity to HER-2-redirected HSV and to
trastuzumab. (A) Cytotoxicity of R-LM249 for cells with high (SK-OV-3,
MDA-MB-453 and BT-474) or very low/negative (MDA-MB-231) HER-2
expression. Cells were infected with R-LM249 (10 pfu/cell). Cell viability
was measured at the indicated days after infection, by alamarBlue assay.
Each point represents the average of quadruplicates + SD expressed as
percentage with respect to uninfected cells. (B) Effect of trastuzumab
after 72 hr culture. Mean and SEM from 3–5 independent experiments
is shown.
doi:10.1371/journal.ppat.1003155.g001
Author Summary
In the genome of human herpes simplex virus (HSV) we
have replaced part of the sequences encoding the
receptor-binding glycoprotein with antibody fragments
directed against the oncoprotein HER-2, overexpressed in
human breast and ovarian cancers. The retargeted HSV
only infects and kills human cancer cells expressing high
levels of HER-2. Earlier experiments showed that the
retargeted HSV injected inside localized tumors inhibits
human tumor growth in immunodeficient mice. As tumor
dissemination is the major cause of cancer mortality, we
have now used the HER-2-retargeted HSV to treat
disseminated HER-2+ ovarian and breast cancer in immu-
nodeficient mice. Intraperitoneal treatments significantly
inhibited the peritoneal spread (carcinomatosis and ascites
formation) of ovarian cancer cells and the metastatic
growth of breast cancer cells in the ovaries. Brain
metastases were also inhibited. Our results showed that
a HER-2-redirected oncolytic HSV is an effective therapeu-
tic agent against metastatic HER-2+ cancers and, more
generally, provide the first demonstration of the efficacy of
a systemically-administered, retargeted oncolytic HSV.
HER-2-Directed HSV Therapy of Peritoneal Spreading
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We took advantage of the EGFP sequence engineered in R-
LM249 genome to monitor intraperitoneal viral spread and to
image the tumors. In this instance, R-LM249 was i.p. adminis-
tered to mice bearing preformed tumors, i.e. 9 weeks after SK-
OV-3 cell injection. The virus populated and replicated in all
visible intraperitoneal tumor masses, producing a strong signal
(Fig. 3F), practically yielding an in vivo imaging of the tumor. EGFP
expression was strictly confined to tumor masses, notwithstanding
the fact that the amounts of administered virus were about 3 logs
higher than those required for wild type virus to kill 100% of mice
by the same route [6]. This finding confirms and extends the high
specificity of R-LM249 towards HER-2-positive cells [6], and
consequently its safety profile. We specify that R-LM249 is
retargeted to human HER-2, hence the virus would likely not be
able to infect cells expressing endogenous murine HER-2, if they
were present. The ability of R-LM249 to infect only cells with a
high level of HER-2 cell surface expression [6], argues that the
virus is unlikely to infect cells with low level of HER-2, i.e. non
cancer cells in which the gene is not amplified.
Cumulatively, the results reported in this section provide the
first evidence that R-LM249 exerts anti-tumor activity against
peritoneally-spread ovary cancers, and that it is effective following
the i.p. systemic route of administration.
Therapy of subcutaneous HER-2+ breast cancer
The primary clinical target of therapeutic agents against HER-2
is breast cancer [19]. As a first approach to evaluate the in vivo
activity of R-LM249 against HER-2+ breast cancer, we studied the
activity of R-LM249 against the growth of subcutaneous tumors
induced by human HER-2+ breast cancer cells. The growth of
MDA-MB-453 and BT-474 tumors in Rag22/2;Il2rg2/2mice was
strongly inhibited by repeated intratumor administrations of R-
LM249 (Fig. 4A and B). R-LM249 was effective both at 26107 and
16108 PFU/mouse, with significantly higher effects for the higher
amount in BT-474 group at several time points, as determined by
Student’s t test. Mice treatment was discontinued at 67 days.
Kaplan-Meier analysis showed that the overall survival was
significantly extended, with about 20% long-term survivors
(Fig. 4C and D). All MDA-MB-453 tumor-bearing mice showed
development of brain and lung metastases.
Therapy of metastases from HER-2+ breast cancer
The visceral organs in the peritoneal cavity are a frequent site of
metastatic spread for breast cancer [14]. The metastatic tropism of
HER-2+ breast cancer in patients is not readily reproduced in
nude mice; recently we reported that Rag22/2;Il2rg2/2 mice
enabled a multiorgan metastatic spread of MDA-MB-453 and BT-
474 cell lines that mirrored the clinical situation, including
ovarian, lung and brain metastases in most mice (Fig. S2 and [18]).
In this model, metastases are induced through cell injection via the
intravenous route, thus allowing to mimic an adjuvant therapeutic
condition. Here, we took advantage of this novel metastatic model
and investigated the therapeutic activity of R-LM249 administered
i.p. against metastases of human breast cancer. We focused on
MDA-MB-453 cells for two reasons. First, these cells are more
metastatic than BT-474 cells. Secondly, their growth is not
inhibited by trastuzumab (see Fig. 1B). Hence, they represent a
worst case scenario of HER-2+ cancer dissemination.
All Rag22/2;Il2rg2/2 mice inoculated i.v. with MDA-MB-453
breast cancer cells developed large ovarian metastases (Fig. S3),
frequently affecting both ovaries. Remarkably, all mice treated i.p.
with R-LM249 appeared free from macroscopic ovarian metas-
tases at necropsy (Fig. 5A).
To quantify micrometastases within mouse ovaries we set up a
quantitative PCR assay for human centromeric sequences (see
Materials and Methods). This molecular assay highlighted that the
numbers of molecularly-detectable human metastatic cells reached
levels significantly lower in the ovaries of virus-treated than in the
ovaries of PBS-treated control mice (Fig. 5B). We found a
therapeutic activity against brain metastases (Figs. 5C–D) and no
effect against lung metastases (Figs. 5E–F).
Since virus replication is dependent on the presence of HER-2+
cells, biodistribution of i.p. administered R-LM249 was studied in
mice already bearing MDA-MB-453 metastases. Virus was found
in ovaries and lungs and, at lower levels, in brain (Fig. 6), with
different kinetics of clearance. Ovaries and brain showed
significantly decreased levels up to 24 hr, then virus level increased
Figure 2. Therapy with the HER-2-redirected oncolytic HSV, R-LM249, of nudemice bearing i.p. human SK-OV-3 ovarian carcinoma.
Red arrows below x-axis mark the days in which groups of 5 mice received weekly i.p. treatments with R-LM249 (26107 p.f.u./treatment) or vehicle
(PBS). Significance of curve comparison: p = 0.02 by the Mantel-Haenszel test.
doi:10.1371/journal.ppat.1003155.g002
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at 48 hr. This suggests that some viral replication occurred in
ovary and brain HER-2+ metastatic deposits, in agreement with
the above reported therapeutic activity. Kinetics of R-LM249 in
lungs was different, with levels unchanged up to 48 hr.
Overall, the i.p.-administered R-LM249 exerted a strong
antimetastatic effect against peritoneal metastases of breast
cancers. Some evidence of therapeutic effect on extraperitoneal
metastases was also found.
Figure 3. Therapy with R-LM249 of Rag22/2;Il2rg2/2 mice bearing i.p. human SK-OV-3 ovarian carcinoma. (A–C) incidence of
peritoneal carcinomatosis, weight of metastatic lesions (mean + SEM) and incidence of ascites fluid in groups of 5–7 mice. Statistically significant
differences: panel B, p = 0.007 at Student’s t test; panel C, p = 0.027 at Fisher’s exact test. (D) control mouse, treated with vehicle (PBS) alone, showing
multiple i.p. masses (green arrows); (E) tumor-free mouse treated with R-LM249; (F) distribution of R-LM249 in a mouse bearing multiple i.p. tumors
shows that the virus selectively populates and replicates in the HER-2+ masses (green fluorescence: virally-encoded EGFP; yellow-brown florescence:
autofluorescence of mouse fur and visceral organs).
doi:10.1371/journal.ppat.1003155.g003
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Discussion
Tumor dissemination is the main cause of cancer-related death.
A major challenge in oncolytic virotherapy is whether viruses can
reach metastatic tumors upon systemic (e.g. intravenous or
intraperitoneal) administration. To address this issue, not previously
investigated for any retargeted HSVs, we employed mouse models
that mirror the intraperitoneal dissemination of the two main HER-
2+ cancers, ovarian and breast. This represents an aggressive,
advanced form of cancer, associated with dismal prognosis. The
HER-2-redirected HSV R-LM249 was administered i.p., to ensure
that it readily reached the intraperitoneal metastatic masses. R-
LM249 strongly inhibited the peritoneal growth of human HER-2+
trastuzumab-resistant ovarian and breast carcinomas, and its
metastatic growth in the brain, but not in the lungs.
Pertinent to our conclusions is the following
(i) HER-2 is a clinically relevant and molecularly attrac-
tive target. Different targeting strategies have led to a range of
specific drugs against the p185 HER-2 oncoprotein. We envision
that the anti-HER-2 virotherapy is not mutually exclusive with the
anti-HER-2 specific therapies, rather they can complement each
other, or be applied sequentially. The monoclonal antibodies
(MAb) and kinase inhibitors (KI) have non-overlapping mecha-
nisms of action, and patients clearly benefit from combinations
[20,21]. An emerging problem is the in vivo selection of cells
resistant to the inhibitors. The HER-2 redirected HSV introduces
a further antitumor tool, independent of MAb and KI.
The distinct advantage of R-LM249 is its cytotoxic activity
independent of tumor cell addiction to HER-2 signaling as well as
of host’s immunity. Whereas KI are efficacious only if tumor
Figure 4. Therapy with R-LM249 of Rag22/2;Il2rg2/2 mice bearing s.c. BT-474 or MDA-MB-453 human breast carcinoma cell lines.
(A) and (B), tumor volumes. R-LM249 was administered intratumorally at the indicated amounts (p.f.u.) on the days marked by red arrows below x-
axis. Mean + SEM of 5 mice per group is shown, until all mice per group are alive. Statistical significance of treatment (at Student’s t test): panel A,
p,0.05 at least from day 13 (108 dose) or 20 (26107 dose); panel B: p,0.05 at least from day 13 (both doses). (C) and (D), Kaplan-Meier analysis. End
of therapy is shown by a vertical dashed line. Median survival times (days) for BT-474 groups were: Vehicle = 73, R-LM249 dose 26107 = 139, dose
108 = 146. Median survival times (days) for MDA-MB-453 groups were: Vehicle = 98, R-LM249 dose 26107 = 125, dose 108 = 132. Survival curves of
treated groups were significantly different from the respective vehicle (p,0.01 at least, Mantel-Haenszel test).
doi:10.1371/journal.ppat.1003155.g004
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growth and survival are dependent on p185 kinase-mediated
signaling, R-LM249 could kill HER-2+ cells independently of
p185 kinase activity. In addition to the inhibition of mitogenic
signaling, anti-p185 MAbs can kill tumor cells through comple-
ment-dependent cytotoxicity or antibody-dependent cell-mediated
cytotoxicity (ADCC). Yet, solid tumors, unlike lymphomas and
leukemias, are mostly resistant to such immune-mediated lytic
mechanisms [22,23]. R-LM249 can kill HER-2+ cancer cells that are
resistant to MAbs, because its cytopathic activity is independent of
tumor cell sensitivity to immune-mediated lysis. So far, we have no
evidence for in vitro selection of cells resistant to R-LM249. As
reported in Results, in Rag22/2;Il2rg2/2 treated mice some residual
Figure 5. Therapy with R-LM249 of systemic metastases induced by the i.v. injection of human breast carcinoma cell line MDA-MB-
453. R-LM249 was administered i.p. at 108 pfu dose (4 weekly injections) to groups of 9–10 Rag22/2;Il2rg2/2 mice. (A, C, E) incidence of
macroscopic metastases in the indicated organs, as determined at necropsy; (B, D, F) total metastatic burden (mean + SEM) in organs as quantified
by human centromeric DNA qPCR. Statistical analysis of differences: panel A, p,0.0001 at Fisher’s exact test; panel B, p = 0.0004 at both Student’s t
and non-parametric Wilcoxon rank sum tests; panel C, p = 0.07 at Fisher’s exact test; panel D, p = 0.056 at Student’s t test and p=0.03 at non-
parametric Wilcoxon rank sum test.
doi:10.1371/journal.ppat.1003155.g005
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small peritoneal masses showed evidence of virus persistence and
replication, indicative of virus-susceptible cells. The presence of R-
LM249–susceptible cells and of the virus possibly reflects a higher
replication rate of the tumor cells relative to that of the virus.
(ii) Current data extend the results of a limited number of
studies on the efficacy of o-HSV following systemic delivery,
with positive indications both in animals and in
humans. In mice, i.p. and i.v. administered non-retargeted o-
HSVs can indeed hamper the growth of tumor masses [24–29],
including i.p. SK-OV-3 xenografts [30]. In humans, administra-
tion of o-HSV via hepatic artery contrasted the growth of
metastatic colon cancers in liver [31–33]. The o-HSVs employed
in the above studies exhibited wt-tropism, hence were capable to
infect, and, albeit at reduced level, to replicate and survive at some
sites before reaching the tumor. By contrast, retargeted HSVs
replicate exclusively after they reach the target tumor and exhaust
themselves when they no longer find susceptible cancer cells.
Similarly, HER-2-retargeted vesicular stomatitis virus (VSV)
administered i.p. could replicate in HER-2+ tumor bearing mice,
but not in tumor-free animals [34].
The systemic administration of HER-2-retargeted HSV to
humans calls for a high safety profile. In vivo, R-LM249 did not kill
any mice, even at doses 3 logs higher than those required for wt-
virus to kill all mice [6]. A limit of that assay was that R-LM249 is
specific to the human HER-2 and likely would not infect cells
expressing the murine HER-2. Safety can be inferred by the highly
specific tropism of the virus for cells that express HER-2, the
requirement for high expression level of the receptor [6], R-
LM249 inability to revert to wt-genotype and phenotype
consequent to the deletion of a large portion of gD gene, and,
finally, the preservation of the thymidine kinase gene that
guarantees the efficacy of acyclovir in a worst case scenario.
(iii) A remarkable finding was the ability of R-LM249 to
reach and populate the tumor masses spread to the
peritoneum. This resulted in EGFP expression in every tumor
mass, even the small ones, and enabled a visualization of
intraperitoneally-spread tumors (Fig. 3F). This property, which
rests on the high specificity of the virus, could lead to the
development of virus-mediated imaging of tumors, particularly
since specific substrates of HSV thymidine kinase were designed,
which enable the detection of HSV-infected cells by the non
invasive, repeatable positron emission tomography (PET) [35].
(iv) The effect of i.p.-administered R-LM249 against
brain metastases most likely reflects the R-LM249 ability
to reach the brain tumors, documented here by detection of
HSV genome copies in the brain (Fig. 6). Alternatively, it
may be consequent to the reduction in peritoneal tumor growth,
should the brain metastases originate from tumor cells leaving the
peritoneal cavity. The differential effect of R-LM249 against
metastasis in different organs could be consequent to microenvi-
ronmental interactions. R-LM249 reached and persisted in lungs,
but was not effective against lung metastases. The high macro-
phage content of lungs could play a role [36].
In previous studies we identified two privileged positions in gD
which can accept single chain antibodies and enable to engineer
fully retargeted o-HSVs [4,5]. A strong advantage of the
technology is that the HER-2-HSVs can be easily re-engineered
to target different oncoproteins, through the replacement of the
trastuzumab-encoding cassette with sequences encoding any other
single-chain antibody, or with sequences encoding natural ligands
to the selected cancer-specific receptors [2]. Thus, the efficacy of
systemically administered retargeted o-HSV reported here will no
doubt impact on the choice of additional targets and on future
developments of retargeted o-HSV.
Materials and Methods
Ethics statement
All animal experiments were performed according to Italian law
116/92 and European directive 2010/63/UE. Experimental
protocols were reviewed and approved by the Institutional Animal
Care and Use Committee (‘‘Comitato Etico Scientifico per la
Sperimentazione Animale’’) of the University of Bologna, and
forwarded to the Italian Ministry of Health with letters 19413-X/
10 (Responsible Researcher Prof. C. De Giovanni) and 20600-X/
10 (Responsible Researcher Prof. P.-L. Lollini).
Cells
Human ovarian cancer cell line SK-OV-3 and human breast
cancer cell lines MDA-MB-453 and BT-474 (all from American
Type Culture Collection, ATCC) were kindly given by Dr.
Serenella M. Pupa (Istituto Nazionale dei Tumori, Milan, Italy).
Cell lines were authenticated by DNA fingerprinting on the 11th
November 2010 (performed by DSMZ, Braunschweig, Germany).
In selected in vitro experiments the MDA-MB-231 cell line (ATCC)
was also used. Cells were cultured in RPMI+10% FBS at 37uC in
a humidified 5% CO2 atmosphere.
Mice
Rag22/2;Il2rg2/2 breeders were kindly given by Drs. T.
Nomura and M. Ito of the Central Institute for Experimental
Animals (Kawasaki, Japan). Mice were then bred in our animal
facilities under sterile conditions and used for the experiments
described here at 10–14 weeks of age. Athymic Crl:CD-1-Foxn1nu/
nu mice (referred to as nude mice) 6-week-old were purchased from
Charles River Italy and kept under sterile conditions.
RLM-249 oncolytic virus
R-LM249 virus was grown in SK-OV-3 and titrated in SK-OV-
3 cells by plaque assay. All experiments were carried out with
partially purified extracellular viruses harvested by high speed
centrifugation.
Cytotoxicity assay
To evaluate the cytotoxic effect of R-LM249, cells were seeded in
96 well plates at 86103 cell/well and infected with R-LM249
(10 pfu/cell) or mock-infected. AlamarBlue (10 ml/well, Life
Technologies) was added to the culture media at 48, 96 and
144 h after infection and incubated for 4 h at 37uC. Plates were
read at 570 and 600 nm with a Synergy HTTR-I fluorometer
(BioTek). For each time point, cell viability was expressed as the
percentage alamarBlue reduction in infected versus uninfected cells,
excluding for each set of samples the contribution of medium alone.
Sensitivity to trastuzumab
Cells were seeded in 96 well plates at 5–106103 cell/well and let
to adhere overnight. Trastuzumab (Genentech Inc.) was then
Figure 6. Biodistribution of R-LM249 injected by the intraperitoneal route at 108 pfu in Rag22/2;Il2rg2/2 mice bearing MDA-MB-
453 metastases. Mean and SEM is shown for 2–3 mice. The number of copies of R-LM249 normalized over the quantity of total DNA extracted from
the organ is reported. ‘‘pre’’ corresponds to organs of a mice that did not receive R-LM249.
doi:10.1371/journal.ppat.1003155.g006
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added to each well at final concentrations ranging 0.001–100 mg/
ml and cultures were incubated for further 72–120 hr. Cell growth
and viability were determined after 1 hr incubation with 1/10
volume of Cell Proliferation Reagent WST-1 (Roche Applied
Science), reading absorbance on an ELISA plate reader with a test
wavelength at 450 nm and a reference wavelength at 630 nm.
Results were expressed as percentage of untreated controls.
Peritoneal carcinomatosis of ovarian carcinoma
For the induction of ovarian cancer peritoneal carcinomatosis,
nude mice or Rag22/2;Il2rg2/2 mice received 26106 ovarian
carcinoma SK-OV-3 cells intraperitoneally (i.p.). R-LM249 was
administered weekly (for five weeks) at 26107–108 plaque-forming
units, starting 3 days after the injection of tumor cells. Nude mice
were sacrificed depending on tumor growth. ForRag22/2;Il2rg2/2
mice, preliminary experiments showed that tumor masses could be
clearly observed as early as 6 weeks after tumor cell injection.
Accurate autopsy was performed with the aid of low-magnification
device and intraperitoneal tumor masses were collected and
weighted to quantify therapeutic efficacy.
Breast carcinoma models
The efficacy of R-LM249 against human HER-2+ breast
carcinoma cells was tested in two experimental systems, i.e.
against the growth of local tumors and against metastases.
For the induction of tumors, cell line MDA-MB-453 was
injected subcutaneously (26106 cells) in a flank of Rag22/2;
Il2rg2/2 mice. R-LM249 was administered weekly (for ten weeks)
at 26107–108 plaque-forming units, starting 3 days after the
injection of tumor cells, as detailed in figure legend. At this time
most mice showed very small but palpable masses, mice were
randomized in the different groups based on tumoral mass size.
Quantification of s.c. tumor masses was assessed weekly (just
before R-LM249 administration) by measuring with a caliper,
tumor volume was calculated as p?[!(a?b)]3/6, where a=maximal
tumor diameter, and b= tumor diameter perpendicular to a [6].
For the induction of metastases, cell line MDA-MB-453 was
injected intravenously (i.v.) (26106 cells). R-LM249 was admin-
istered weekly (for four weeks) at 26107–108 plaque-forming units,
starting 3 days after the injection of tumor cells. Mice were
sacrificed 10 weeks after tumor cell injection. Incidence of
macroscopic metastases was determined at necropsy. Metastatic
burden was estimated by human centromeric DNA qPCR
quantification on genomic DNA of dissected organs (ovaries,
brain and lungs). Human centromeric DNA qPCR quantification
of metastatic burden in dissected organs (ovaries, brain and bone
marrow) was performed by Real-Time PCR performed on
genomic DNA, extracted with 10 mM Tris-HCl buffer pH 8.3
containing 50 mM KCl, 2.5 mM MgCl2, 0.01% gelatin, 0.45%
Igepal, 0.45% Tween 20 and 120 mg/ml proteinase K (all reagents
from Sigma, Milan, Italy) by an overnight incubation at 56uC
followed by 30 min incubation at 95uC to inactivate the proteinase
K. A sequence of the a-satellite region of the human chromosome
was amplified. Primer and probe sequences derived from Becker et
al. [37] with the sole alteration that the probe carried the non-
fluorescent quencher dye TAMRA at the 39-end. A 100 ng DNA
aliquot per sample was amplified using 250 nM primers and
100 nM probe in a final volume of 25 ml of TaqMan Universal
PCR Master Mix (Applied Biosystems, Milan, Italy). After an
initial denaturation step at 95uC for 10 min, 45 cycles of
amplification (95uC for 30 sec plus 60uC for 1 min) were
performed in a 5700 Sequence Detection System (Applied
Biosystems). DNA extracted from mouse tissues showed no
amplification up to 45 cycles. To quantify human cells, standard
curves were constructed by adding serial amounts of MDA-MB-
453 human cells (from 100% to 0.001%) to fixed amounts of
mouse cells or mouse whole brain. Ct (threshold cycle) values
obtained from the experimental samples were interpolated in the
standard curve run in each PCR to obtain the relative amount of
human to murine cells in the sample (referred to as human DNA
relative units). Three to five independent determinations were
performed for each specimen.
Biodistribution of R-LM249
R-LM249 was injected i.p. at 108 pfu in 0.4 ml in Rag22/
2;Il2rg2/2 mice bearing metastases from MDA-MB-453 (7 weeks
after the i.v. injection of cells as reported above). Mice were
sacrificed at various times (0.5, 6, 24 and 48 hr after virus
injection). Ovaries, lungs and brain were collected at sacrifice and
immediately frozen. DNA was then extracted with NucleoSpin
Tissue (Macherey-Nagel) accordingly to the manufacturer’s
instruction and subjected to qPCR, with a standard curve of
known quantities R-LM249 (from 25000 to 8 viral genome copies)
performed in parallel. Primers used were: gG_504_f CTTG-
GTTCCGACGCCTCAACATAC and gG_603_r TAAGGTGT-
GGATGACGGTGCTGAC.
Statistical analysis
Tumor-free survival curves (Kaplan–Meier) were compared by
the Mantel-Haenszel test. Tumor volumes and tumor or
metastatic burdens were compared by the Student’s t test and
the non-parametric Wilcoxon rank sum test. Frequencies of mice
with metastases were compared by Fisher’s exact test.
Supporting Information
Figure S1 Dissemination of human SK-OV-3 ovarian carcinoma
in the peritoneal cavity of Rag22/2;Il2rg2/2 mice. Each panel
shows multiple tumor nodules in one mouse 6 weeks after an i.p.
challenge with 26106 cells. (A) Multiple nodules adhering to the
omentum between liver and stomach; (B) Large nodules underneath
the liver; (C) three nodules in the lower peritoneal cavity (detail of
mouse of Figure 3d); (D) a large mass behind uterine horns.
(TIF)
Figure S2 Intracerebral MDA-MB-453 metastases in Rag22/
2;Il2rg2/2 mice evidenced by immunohistochemical staining for
HER-2 (in brown). Mice received the i.v. injection of 26106
MDA-MB-453 cells. Numerous metastases preferentially localised
in the cerebral cortex were observed. Most metastases initially
appear as intravascular metastases (A) invading the brain
parenchyma by direct extension (C) or along blood vessels (B, D).
(TIF)
Figure S3 Ovarian metastasis in a Rag22/2;Il2rg2/2 mouse 10
weeks after the i.v. injection of 26106 MDA-MB-453 breast
cancer cells.
(TIFF)
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